Introduction
The overall mortality from acute poisoning among the 100 000 patients admitted each year to hospitals in England and Wales is now less than 1% (Goulding, 1974) , and most of the patients recover physically without any special treatment. The remainder are treated supportively along the lines first advocated by Clemmesen and Nilsson (1961) . While there can be no substitute for such good medical and nursing care there is, nevertheless, a small group of very severely poisoned patients for whom some active means of removing the drug would be advantageous in addition to the basic supportive measures. Efficient methods to promote, for example, the excretion of central nervous system depressant drugs might not only reduce the length of coma, and as a result the number and severity of the complications occurring in such patients, but could also reduce the mortality (Vale, 1974) .
Three methods are currently available for this purposeforced diuresis, peritoneal dialysis, and haemodialysis. Forced alkaline diuresis is indicated only for phenobarbitone, barbitone, and salicylate poisoning; forced acid diuresis is indicated only in severe acute amphetamine and quinine poisoning; and peritoneal dialysis seems to have an established place only in the management of lithium overdose. Haemodialysis, moreover, has not so far proved convincing in the care of patients with overdoses of the short-and medium-acting barbiturates and the non-barbiturate hypnotics, which are responsible for many of the serious and fatal poisonings in this country.
A further method has recently become available for clinical use. Haemoperfusion, the passage .of blood through various adsorbent materials, including charcoal, combines efficacy with relative simplicity, but its use has hitherto been restricted because of complications including embolism, marked thrombocytopenia, leucopenia, fibrinogen loss, and pyrexial reactions. Many of these side effects have now been overcome by coating the charcoal (Chang et al., 1973 Cace 2. A nurse of 23 years was found unconscious at home by her husband. An empty bottle of phenobarbitone was found beside her. On admission to hospital she had evidence of pneumonia and was deeply unconscious (grade 4), hypotensive (90/60 mm Hg), hypothermic (26°C), and required ventilation. A forced alkaline diuresis was begun and 22 hours after the overdose had been taken the patient was transferred to Guy's Hospital for haemoperfusion. Toxicological analysis had indicated that the level immediately before perfusion was 1121 Amol/l. (26 mg/ 100 ml).
Forty-five minutes after beginning haemoperfusion the patient was taken off the ventilator, but perfusion was continued for six hours altogether, by which time the level of consciousness had improved to grade 2. A drug clearance of 120 ml/min was achieved with a calculated removal of 5472 mg phenobarbitone during perfusion, compared with 1806 mg excreted in the urine over 36 hours. The platelet counts before and at the end of perfusion were 130 x 109/1. (130 000/min3) and 62 x 109/1. (62 000/mm3) respectively.
Case 3.-A 31-year-old medical practitioner was found unconscious in his room 34 hours after taking 167 phenobarbitone tablets and half a bottle of whisky. When transferred to an intensive care unit he was deeply comatose (grade 4), hypotensive (70/30 mm Hg), anoxic (Po2 4-4 kPa (33 mm Hg)), and had a leftsided pneumonia. The 
Biochemical and Haematological Tests
Blood was taken both before and after and sometimes during perfusion for estimation of electrolytes, urea, calcium, phosphate, alkaline phosphate, glucose, proteins, bilirubin, cholesterol, aspartate and alanine aminotransferases, urate, creatinine, fatty acids, fat soluble vitamins, blood picture, coagulation profile, and drug levels. In addition, samples were taken during perfusion for estimation of drug levels (pre-and post-column), platelet, leucocyte, and heparin levels. The biochemical and haematological estimations were carried out by routine techniques: heparin concentrations were determined by a modification of the method of Pitney (1968) and drug levels were measured by a specific gas liquid chromatographic technique (Flanagan and Withers, 1972 Conversion: SI to Traditional Units-Phenobarbitone: 1 ,umol/l Rs 0-0212 mg/100 ml. diagnostic rather than therapeutic reasons. It was thought that if no improvement ensued after drug removal the patients were likely to have suffered irreversible cerebral damage secondary to anoxia. A decision could then be made as to whether to turn off the ventilator in hours rather than days. In fact the patient in case 5 suffered a further cardiorespiratory arrest after a short period of complete heart block and could not be resuscitated. No improvement in his condition was noted, however, despite the fact that the plasma pentobarbitone level had by then been reduced to 89 psmol/l. (2 mg/100 ml). The patient in case 6 was moribund on arrival; he was hypothermic, had an unrecordable blood pressure, was in acute renal failure, required ventilation, and manifested a variety of cardiac arrhythmias. Despite a reduction of the plasma butobarbitone level to 90 ,umol/l. (1-9 mg/100 ml), the patient showed no signs of recovery.
In the light of our initial results we would not consider it ethically justifiable to place very severely poisoned patients in a non-haemoperfused control group. Nevertheless, we were able to observe a comparable patient who was energetically treated by conventional means. The similarity between this patient (case 7) and the patient in case 2 on admission was striking (table I) yet the outcome was so different. The plasma drug concentration profiles are shown in fig. 3 . The nonhaemoperfused patient died four days after taking the overdose from the "shock-lung" syndrome. 1 ,umol/l w 0-023 mg/100 ml.
EFFECTS ON PLATELETS AND LEUCOCYTES
In each of the four patients who recovered there was a fall in the platelet count, usually within 30 minutes of beginning haemoperfusion, which was followed by a spontaneous rise over the next two to three days to levels similar to those found initially. Two of the four patients had postperfusion platelet counts greater than those found initially. The two patients who died (cases 5 and 6) both had initial platelet counts below 100 x 109/1. (100 000/mm8) with a fall of 54% and 41% respectively in their platelet levels whereas the mean reduction in platelet levels between beginning haemoperfusion and discontinuing the procedure for the group as a whole was 38% (range 16-54%). The highest percentage reduction occurred in the patient in case 5, who had bled from a failed subclavian vein cannulation. Except in this patient there was no evidence of bleeding or mucosal haemorrhages during or after haemoperfusion.
Within one hour of beginning haemoperfusion in case 4 a second column had to be introduced into the circuit because of clotting due to the use of a new heparinization schedule which proved inadequate. There was no further fall in platelet count after this, which confirmed our experience with animals that there is little platelet deposition on coated charcoal. The bubble trap is probably responsible for much of the platelet loss and we are currently investigating this with radioactive platelet labelling.
A slight fall in leucocyte levels was found on beginning haemoperfusion but this was usually followed by a moderate rebound so that by the end of perfusion the leucocyte level was higher than the preperfusion level.
BIOCHEMICAL CHANGES
Though many biochemical values were investigated during haemoperfusion there was no change in the arterial concentration of any of these with the exception that in case 5 there was a fall in the patient's plasma urate and cholesterol levels to 1-5 mmol/l. (2.5 mg/100 ml) and 2-1 mmol/l. (80 mg/100 ml) respectively. We found no fall in the plasma glucose level on beginning perfusion, in contrast to the findings reported by Gazzard et al. (1974) . The fact that some of the patients were receiving glucose intravenously, however, may have partly masked this effect in our patients.
Discussion
The adsorbent action of charcoal has been known for many years. Andersen (1948) , for example, showed its ability to adsorb barbiturates, and some would advocate its routine use as an oral antidote for ingested toxic substances (Holt and Holz, 1963; Corby et al., 1970) . Yatzidis (1964 a, b; Yatzidis et al., 1965) was the first to describe the use of charcoal haemoperfusion for the removal of creatinine, urate, phenols, guanides, salicylates, barbiturates, and glutethimide. Dunea (1962, 1968) investigated the use of anion-exchange 9 resins, but complications persisted. Rosenbaum et al. (1970 Rosenbaum et al. ( , 1971 have successfully overcome some of these by using an uncharged resin, Amberlite XAD-2, in animals and patients. In dogs the value of XAD-2 haemoperfusion and its superiority over haemodialysis has been reported (Medd et al., 1973) , but thrombocytopenia and leucopenia occurred and, also, pyrexial reactions are known to arise in man. This resin was also found later to have a limited drug saturation capacity (unpublished results).
Attempts were therefore made to eliminate the disadvantages of charcoal by coating it with cellulose acetate (Yatzidis, 1967; Rosenbaum, 1968) , collodion, collodion and albumin, heparincomplexed collodion, nylon (Chang et al., 1967 (Chang et al., , 1968 Chang, 1969; Chang and Malave, 1970) , glutaraldehyde cross-linked bovine albumin (Andrade et al., 1972) , and polyhydroxyethyl methacrylate (polyHEMA), a synthetic hydrogel (Andrade et al., 1971) .
The successful use of an acrylic hydrogel coated charcoal haemoperfusion system for the removal of paracetamol in pigs (Willson et al., 1973) and a variety of drugs in dogs (Widdop et al., 1975) and in the treatment of liver failure (Gazzard et al., 1974) has been described. Charcoal coated in this way overcomes many of the disadvantages associated with uncoated material without seriously reducing its absordtive ability.
There was some reduction in the platelet count in each of the six patients, being greatest in the two who died, but the thrombocytopenia which we observed was of a similar order to that seen in haemodialysis (Lawson et al., 1966; Lindsay et al., 1972) and less severe than that encountered in cardiac bypass operations (Barkhan, 1967) . Furthermore, in the four patients who recovered the platelet count returned to normal over the two to three days after haemoperfusion. In addition, there was no evidence of charcoal embolism.
Our results show that charcoal haemoperfusion is a most efficient method for increasing the elimination of all types of barbiturates and glutethimide. This is confirmed by a comparison of the clearance data obtained from the use of various techniques which increase drug elimination (table II) . Animal work (Widdop et al., 1975) suggests that haemoperfusion may also be the best method available for promoting the excretion of methaqualone, salicylates, ethchlorvynol, trichloroethanol, and meprobamate. We advocate the use of charcoal haemoperfusion in the following cases: in patients in whom there is evidence of severe clinical intoxication; in severely poisoned patients who fail to improve despite the use of supportive measures; in patients in prolonged coma with such complications as pneumonia and underlying chronic respiratory disease; and in patients who are deeply unconscious and have suffered a cardiorespiratory arrest of brief duration and require ventilation. In this condition the rapid elimination of the drug allows a diagnosis of cerebral damage and, therefore, a decision about future management can be made in hours rather than in days.
In conclusion, we believe that charcoal haemoperfusion-a technique that is both simpler and more effective than haemodialysis-may have a significant role to play in the management of the very severely poisoned patient.
